AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$CBIO

Brumm Joshua T sold $160K of CBIO

Brumm Joshua T (Chief Executive Officer) sold 9,447 shares of CRESCENT BIOPHARMA, INC. (CBIO) at an average of $16.91 ($16.71–$17.90, $0.16M total) across 2 trades over 2026-09-16 to 2026-09-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brumm Joshua T
Published Sep 18, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CBIO
Neutral
high confidence
Mentioned
$CBIO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBIONeutralLow
01

Why it matters

The transaction is routine and does not alter the company's fundamentals.

02

Market read

Insider sale of modest size; limited trading relevance.

03

What to watch

Potential upcoming corporate events not disclosed.

Relevance 3/10Novelty 3/10Timing: filed today

Background

SEC Form 4 filing discloses insider transactions.

Company-level read

Ticker impact

$CBIONeutralHigh confidence
Context

CEO Brumm Joshua T sold 9,447 shares for $159,775 via a 10b5-1 plan, reducing his stake to 271,765 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

Sale size is small relative to market cap and disclosed as a routine 10b5-1 transaction.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Sale could signal insider confidence if viewed as portfolio rebalancing.

Key entities

  • Company
    Crescent Biopharma, Inc.

    Biopharma company listed on NASDAQ.

  • Person
    Brumm Joshua T

    Chief Executive Officer of Crescent Biopharma.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CBIO insider trading history →

Related articles

JUL 30
$CBIOMed

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treate

SEC EDGAR 8-K4 min
JUL 14
$CBIOLow

CRESCENT BIOPHARMA, INC. (CBIO): Results of Operations and Financial Condition

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. cbio-20260714 0001253689 false 0001253689 2026-07-14 2026-07-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________________________________________________ FORM 8-K ______________________________________

SEC EDGAR 8-K1 min